AI's Role in Accelerating Drug Development and Clinical Trials with Raphael Townshend, PhD, Founder and CEO of Atomic AI

AI and RNA are revolutionizing drug discovery, promising a future where life-saving medications are developed faster and at lower costs.

In this episode, Raphael Townshend, PhD, Founder and CEO of Atomic AI, sits down with me to discuss the intersection of AI and RNA in drug development. We explore how AI technologies can reduce the cost and time required for clinical trials and target previously incurable diseases.

Key Takeaways:

(02:15) Raphael's background in AI and biology, and founding of Atomic AI.

(05:59) Reducing time and failure rate in drug discovery with AI.

(07:16) AlphaFold's breakthrough in understanding molecular shapes using AI.

(09:23) Ensuring transparency and accountability in AI-driven drug discovery.

(12:22) Navigating intellectual property concerns in healthcare AI.

(15:34) Integrating AI with wet lab testing for accurate drug discovery results.

(17:31) Balancing intellectual property and open research in biotech.

(20:02) Addressing data privacy and security in AI algorithms.

(22:30) Educating users and healthcare professionals about AI in drug discovery.

(24:48) Collaborating with global regulators for AI-driven drug discovery innovations.

Resources Mentioned:

Raphael Townshend -

https://www.linkedin.com/in/raphael-townshend-9154962a/

Atomic AI | LinkedIn -

https://www.linkedin.com/company/atomic-ai-rna/

AlphaFold -

https://deepmind.google/technologies/alphafold/

Atomic AI Homepage -

https://atomic.ai/

ATOM-1 Large Language Model -

https://www.biospace.com/atomic-ai-creates-first-large-language-model-using-chemical-mapping-data-to-optimize-rna-therapeutic-development

Thanks for listening to the Regulating AI: Innovate Responsibly podcast. If you enjoyed this episode, please leave a 5-star review to help get the word out about the show. And be sure to subscribe so you never miss another insightful conversation.

#AIRegulation #AISafety #AIStandard